title: Evidence of improving antiretroviral therapy treatment delays: an analysis of eight years of programmatic outcomes in Blantyre, Malawi.
abstract: BACKGROUND
  Impressive achievements have been made towards achieving universal coverage of antiretroviral therapy (ART) in sub-Saharan Africa. However, the effects of rapid ART scale-up on delays between HIV diagnosis and treatment initiation have not been well described.
  
  
  METHODS
  A retrospective cohort study covering eight years of ART initiators (2004-2011) was conducted at Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi. The time between most recent positive HIV test and ART initiation was calculated and temporal trends in delay to initiation were described. Factors associated with time to initiation were investigated using multivariate regression analysis.
  
  
  RESULTS
  From 2004-2011, there were 15,949 ART initiations at QECH (56% female; 8% children [0-10 years] and 5% adolescents [10-20 years]). Male initiators were likely to have more advanced HIV infection at initiation than female initiators (70% vs. 64% in WHO stage 3 or 4). Over the eight years studied, there were declines in treatment delay, with 2011 having the shortest delay at 36.5 days. On multivariate analysis CD4 count <50 cells/μl (adjusted geometric mean ratio [aGMR]: aGMR: 0.53, bias-corrected accelerated [BCA] 95% CI: 0.42-0.68) was associated with shorter ART treatment delay. Women (aGMR: 1.12, BCA 95% CI: 1.03-1.22) and patients diagnosed with HIV at another facility outside QECH (aGMR: 1.61, BCA 95% CI: 1.47-1.77) had significantly longer treatment delay.
  
  
  CONCLUSIONS
  Continued improvements in treatment delays provide evidence that universal access to ART can be achieved using the public health approach adopted by Malawi However, the longer delays for women and patients diagnosed at outlying sites emphasises the need for targeted interventions to support equitable access for these groups.
authors.affiliation: Malawi-Liverpool-Wellcome Trust and Liverpool School of Tropical Medicine, Chichiri 3, PO 30096, Blantyre, Malawi.
authors.forename: Derek J
authors.initials: DJ
authors.lastname: Sloan
authors.forename: Joep J
authors.initials: JJ
authors.lastname: van Oosterhout
authors.forename: Ken
authors.initials: K
authors.lastname: Malisita
authors.forename: Eddie M
authors.initials: EM
authors.lastname: Phiri
authors.forename: David G
authors.initials: DG
authors.lastname: Lalloo
authors.forename: Bernadette
authors.initials: B
authors.lastname: O'Hare
authors.forename: Peter
authors.initials: P
authors.lastname: MacPherson
mesh_terms: D000293:Adolescent; D000328:Adult; D044966:Anti-Retroviral Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy*; D006297:Health Services Accessibility / Q000706:statistics & numerical data*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008295:Malawi; D008297:Male; D008875:Middle Aged; D009313:National Health Programs; D012189:Retrospective Studies; D061665:Time-to-Treatment / Q000592:standards*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D044966:Anti-Retroviral Agents